# 2014 OPA Annual Conference Learning Objectives

#### ACPE #0129-0000-14-016-L01-P

### **Antidepressants: A New Decade**

Randy A. Sansone, MD, Professor, Psychiatry & Internal Medicine, Wright State University School of Medicine At the completion of this activity, the participant will be able to:

- 1. describe an acronym for the ordering of the tricyclic antidepressants;
- 2. identify the three formulations of bupropion;
- 3. identify two second-generation antidepressants that are congeners;
- 4. describe an acronym for the ordering of the selective serotonin reuptake inhibitors;
- 5. describe for the SNRIs the proportionate effects on serotonin and norepinephrine reuptake; and
- 6. identify two antidepressants with SSRI activity plus additional actions.

## ACPE #0129-0000-14-017-L04-P

# Medicare Update: Impact of Health Care Reform

Todd Stankewicz, CAPT, U.S. Public Health Service

Pharmacist - CMS Region V, Chicago

At the completion of this activity, the participant will be able to:

- 1. describe how Health Care Reform and the development of "marketplaces" will impact Medicare beneficiaries;
- 2. discuss changes to the Medicare Prescription Drug benefit in 2014/2015; and
- 3. identify resources available to pharmacists to facilitate understanding of Medicare changes as a result of the Affordable Care Act.

#### ACPE #0129-0000-14-018-L01-P

## **Current Trends in Outpatient Anticoagulation Management**

*Karen Knoell, PharmD, R.Ph., Staff Pharmacist, OhioHealth, McConnell Heart Health Center Anticoagulation Clinic* At the completion of this activity, the participant will be able to:

- 1. explain rationale for "bridge" therapy in patients who require interruption of warfarin for procedures;
- 2. describe risk assessment tools, such as CHADS2 score, in determining which patients may benefit from "bridge" therapy;
- 3. review patient education for "bridge" therapy, including injection technique for injectable anticoagulants;
- 4. discuss clinical trials that resulted in FDA approval of Novel Oral Anticoagulants, dabigatran, rivaroxaban and apixiban; and
  - 5. compare Novel Oral Anticoagulants (NOAC) to warfarin, and discuss their place in therapy.

### ACPE #0129-0000-14-019-L04-P

## What's Next: The Ever Changing Landscape of Pharmacy Compounding

Lee Rosebush, PharmD, J.D., M.B.A., M.S, BakerHostetler, Washington, D.C.

At the completion of this activity, the participant will be able to:

- 1. review portions of the Drug Quality and Security Act and its impact on pharmacy compounding;
- 2. discuss recent Food and Drug Administration (FDA) guidance documents and their impact on both outsourcing facilities and traditional pharmacies; and
  - 3. review United States Pharmacopeia (USP) standards and their recent adoption by FDA.

# ACPE #0129-0000-14-020-L01-P

#### The New JNC Guidelines - Finally!!!

Vincent F. Mauro, R.Ph., PharmD, Professor of Clinical Pharmacy

The University of Toledo College of Pharmacy and Pharmaceutical Sciences

- 1. identify what blood pressures trigger a need to start antihypertensive therapy;
- 2. state the goal of therapy when treating hypertension;
- 3. list which antihypertensive medications are preferred;
- 4. explain how to treat a patient with difficult to control hypertension; and
- 5. discuss important clinical perspectives of medications commonly used to treat hypertension

# ACPE #0129-0000-14-021-L01-P

# **OTC/Self-Care Updates 2014**

Daniel L. Krinsky, MS, R.Ph., Manager of MTM Programs at Giant Eagle Pharmacy and Associate Professor of Pharmacy Practice at NEOMED; and Timothy R. Ulbrich, PharmD, Director of Pharmacy Resident Education and Assistant Professor of Pharmacy Practice at NEOMED

At the completion of this activity, the participant will be able to:

- 1. list OTC/Self-care products that entered the market during the past year;
- 2. identify OTC/Self-care products that had safety concerns and/or recalls issued in the past year;
- 3. list recent legal and regulatory activities related to OTC/self-care products;
- 4. discuss recent research published for existing OTC products; and
- 5. summarize key patient counseling points based on OTC/Self-care updates that took place in the past year.

#### ACPE #0129-0000-14-022-L04-P

#### **Guiding Behavior Change through Motivational Interviewing**

Randi Love, PhD, MCHES, Clinical Associate Professor

Division of Health Behavior/Health Promotion, OSU College of Public Health

At the completion of this activity, the participant will be able to:

- 1. identify the differences between the traditional clinical encounter and the encounter incorporating motivational interviewing;
  - 2. describe the stages of change;
  - 3. identify the primary skills and strategies associated with motivational interviewing; and
  - 4. apply the primary skills and strategies associated with motivational interviewing.

## ACPE #0129-0000-14-023-L04-P

## **Ohio Research Forum 2014**

Moderator: Timothy R. Ulbrich, PharmD, Director of Pharmacy Resident Education and Assistant Professor of Pharmacy Practice at NEOMED

At the completion of this activity, the participant will be able to:

- 1. identify research projects being conducted by pharmacists, student pharmacists and faculty at the colleges of pharmacy in Ohio;
- 2. explain the results of these research projects in terms of the effective delivery of medication;
- 3. describe the impact these research projects on medication therapy management services and the contemporary practice of pharmacy; and
- 4. explain the pharmacoeconomic issues associated with this research.

## ACPE #0129-0000-14-024-L04-P

### MTM Success in Ohio Medicaid-Results That Matter!

Craig Thiele, MD, Chief Medical Officer, CareSource; Jim Gartner, R.Ph., MBA, VP, Pharmacy and Medical Management Services, CareSource; Tim Sullivan, R.Ph., PharmD, Director of Clinical Services, OutcomesMTM At the completion of this activity, the participant will be able to:

- 1. discuss the roll out of the Ohio Medicaid medication therapy management (MTM)program;
- 2. identify extensions of the services provided to patients by pharmacists; and
- 3. explain the clinical successes resulting from implementation of the Ohio Medicaid MTM program and how this program has become a model for other states.

#### ACPE #0129-0000-14-025-L01-P

# Community-Acquired Infections - Utilizing Treatment Guidelines to Evaluate Prescriptions

Andrew M. Roecker, PharmD, RPh, BCPS – Chair and Professor of Pharmacy Practice, Ohio Northern University At the completion of this activity, the participant will be able to:

- 1. list common infections seen in patients presenting to the community pharmacy;
- 2. explain the difference between common bacterial and viral presentations, based upon the specific infection with which the patient presents ;
- 3. describe appropriate antimicrobial and non-pharmacologic options for treating and preventing infections in the community setting; and
- 4. discuss the utilization of current therapeutic guidelines for infections presenting to the community pharmacy.

#### ACPE #0129-0000-14-026-L04-P

#### **Ohio Innovative Practice Forum 2014**

Jennifer Rodis, PharmD, BCPS, Director, Partner for Promotion Program, OSU College of Pharmacy; Timothy R. Ulbrich, PharmD, Director, Partner for Promotion Program, NEOMED College of Pharmacy; and Panel of Practitioners At the completion of this activity, the participant will be able to:

- 1. describe innovative pharmacy practice models in Ohio;
- 2. identify how individual pharmacy practices and practitioners are expanding patient care services statewide;
- 3. describe the successes and challenges of these programs including their financial viability and impact on outcome measures; and
- 4. apply these ideas, opportunities, and resources to enhance his/her own pharmacy practice.

# ACPE #0129-0000-14-027-L04-P

# Collaboration in Quality: PQS, CMS STARS, Plans and Pharmacies

Elliott M. Sogol, PhD, R.Ph., FAPhA

Vice President Professional Relations, Pharmacy Quality Solutions, Inc.

At the completion of this activity, the participant will be able to:

- 1. describe Value Driven Health Care;
- 2. describe the CMS Star ratings process as it relates to medications;
- 3. identify performance improvement strategies related to medication management in the Star ratings process;
- 4. explain the reasoning for measuring the quality of medication use; and
- 5. discuss where plans are headed related to the quality of medication use

## ACPE #0129-0000-14-028-L01-P

# **Hepatitis C Virus Therapy Update**

April Delahunty, PharmD, BCPS

Specialty Practice Pharmacist, Solid Organ Transplant, OSU Wexner Medical Center

At the completion of this activity, the participant will be able to:

- 1. review and differentiate the types of chronic viral hepatitis;
- 2. discuss treatment options for patients with chronic Hepatitis C virus (HCV); and
- 3. review novel HCV therapies: sofosbuvir, simeprevir, and daclatasvir

# ACPE #0129-0000-14-029-L04-P

## Integrated Medication Management: The Pharmacist's Role on the Ambulatory Care Team

Jennifer Clark, R.Ph., Director of Pharmacy Services and Josh Ebbing, PharmD, PGY1 Resident, Health Partners of Western Ohio, Lima

At the completion of this activity, the participant will be able to:

- 1. discuss strategies used to develop an integrated care team;
- 2. identify ten elements of integrated medication management;
- 3. explain the value of the pharmacist on the care team; and
- 4. describe methods for documenting medication safety interventions.

#### ACPE #0129-0000-14-030-L03-P

### Ohio Law Update 2014

Kyle W. Parker, MBA, R.Ph., Executive Director and Tracy Nave, Director of Legal Affairs, Ohio State Board of Pharmacy

At the completion of this activity, the participant will be able to:

- 1. identify recent changes in state and federal laws and regulations which impact pharmacy practice;
- 2. describe the 80 Morphine Equivalency Dosing (MED) threshold and what it means for prescribers and pharmacists;
- 3. explain how to interpret OARRS reports for case examples; and
- 4. apply the recent changes in state and federal laws and regulations to his/her specific practice of pharmacy.

# ACPE #0129-0000-14-031-L01-P

## Seniors and Medications: Too Many? Too Late? What to do?

Sean M. Jeffery, PharmD, CGP, FASC, Clinical Professor, University of Connecticut; and Chair, Board of Directors, American Society of Consultant Pharmacists

- 1. discuss societal and healthcare implications of increasing longevity in America;
- 2. identify medication-related "tipping points" that increase risk and result in poor outcomes in seniors;
- 3. review common "high-risk" medications frequently used in seniors;
- 4. discuss a framework for managing complex, comorbid older adults medications; and
- 5. list tips on counseling older adults who may have altered states of cognition.

#### ACPE #0129-0000-14-032-L04-P

#### **Putting Your Best Foot in the Door!**

Marialice Bennett, R.Ph., FAPhA, Emeritus Professor, The Ohio State University College of Pharmacy At the completion of this activity, the participant will be able to:

- 1. explore ways to sell the role of the pharmacist in the new health care environment;
- 2. identify mechanisms to begin a new interprofessional practice or initiate a new relationship with a physician;
- 3. explain how to use a SWOT analysis to turn weaknesses into strengths and threats into opportunities;
- 4. describe ways to address resistance from other health care providers; and
- 5. develop skills to become a team player.

## ACPE #0129-0000-14-033-L01-P

#### **Addiction Concerns for Pharmacists**

Jarrod Grossman, PharmD, R.Ph., and Nick Kallis, R.Ph., Pharmacists Rehabilitation Organization

At the completion of this activity, the participant will be able to:

- 1. recognize the risk factors, signs and symptoms of addiction;
- 2. describe the recovery process of addiction;
- 3. list self-care and prescription medication concerns for the recovering addict; and
- 4. discuss recovery assistance that is available for impaired pharmacists and pharmacy interns.

#### ACPE #0129-0000-14-034-L04-P

#### **Ohio's MTM Story**

Moderator: Justin Friesner, PharmD, Pharmacy Coordinator, The Kroger Co.; and Panel of Practitioners from OPA's DSM Task Force MTM Workgroup

At the completion of this activity, the participant will be able to:

- 1. describe current MTM programs in the state of Ohio;
- 2. explain the methods to initiate each program in various settings of pharmacy;
- 3. discuss examples of billing MTM in multiple practice sites; and
- 4. recognize the value of educating the public of current MTM stories in the state of Ohio.

#### ACPE #0129-0000-14-035-L01-P

## Pharmacogenetics: Clinical Application of Population and Individual Preemptive Genetic Data

David F. Kisor, PharmD, Professor of Pharmacokinetics and David R. Bright, PharmD, Assistant Professor of Pharmacy Practice, Raabe College of Pharmacy, Ohio Northern University

At the completion of this activity, the participant will be able to:

- 1. recognize the most common forms of genes relative to pharmacokinetics and pharmacodynamics in various populations;
  - 2. compare and contrast preemptive and "reactionary" pharmacogenetic testing;
  - 3. design a dosage regimen based on an individual's genotype;
- 4. interpret pharmacogenetic testing results; and
- 5. recognize the current limitations of pharmacogenetic testing.

## ACPE #0129-0000-14-036-L04-P

# **Pharmacy Career Trends**

Donald Bennett, R.Ph., MBA, Director of Professional Experiential Programs, The Ohio State University College of Pharmacy

At the completion of this activity, the participant will be able to:

- 1. discuss recent trends in the supply of pharmacists;
- 2. discuss the current and future projected changes in the demand for pharmacists including professional services, practice settings, and geographical differences; and
- 3. discuss strategies for pharmacists to increase our impact on health and wellness of patients in the changing U.S. health care system.

## ACPE #0129-0000-14-037-L04-P

# **Innovative Pharmacy Business Plan Competition 2014**

Finalist teams and panel of judges TBA

- 1. identify essential components of a business plan, including mission statement, description of business, loan request, marketing plan and financial reports;
- 2. explain the importance of effective visual aids and nonverbal communication during presentation of a business plan; and
- 3. recognize how enthusiasm, professionalism and completeness can impact the effectiveness of a business plan presentation.

#### ACPE #0129-0000-14-038-L01-P

#### MTM for the Diabetes Patient

Kevin Fuschetto, R.Ph., PharmD, BCACP, Clinical Coordinator, Giant Eagle Pharmacy

At the completion of this activity, the participant will be able to:

- 1. discuss Medication Therapy Management (MTM) and its use for the patient with diabetes;
- 2. describe the impact of the Medicare STAR Ratings on MTM;
- 3. apply techniques related to Motivational Interviewing to enhance communication and encourage healthy choices; and
- 4. review the current treatment goals and strategies for patients with diabetes.

# ACPE #0129-0000-14-039-L04-P

# **Preceptor Development Tools**

Tonya Dauterman, University of Findlay; Scott Wisneski, NEOMED; Jennie Kline, Ohio Northern University; Thad Franz, Cedarville University

At the completion of this activity, the participant will be able to:

- 1. explain the importance of setting rotation expectations providing key elements to student orientation:
- 2. outline learning objectives and syllabus for his/her rotation focus;
- 3. describe how to provide valuable feedback to the students early and often (formative & summative);
- 4. identify the root cause of a challenging student (professionalism, academics or culture); and
- 5. list strategies to manage a challenging student.

#### ACPE #0129-0000-14-040-L04-P

## Conservative Prescribing: The Role of the Pharmacist

Bradley Shinn, PharmD, Associate Professor of Pharmacy Practice, University of Findlay College of Pharmacy At the completion of this activity, the participant will be able to:

- 1. define "conservative prescribing" and "evidence-based medicine.";
- 2. identify the common types of medication misadventures and assess the overall impact on the quality and cost of U.S. healthcare;
- 3. define "prescribing inertia" and discuss how this relates to overprescribing and polypharmacy;
- 4. compare and contrast the use of clinical guidelines vs. the use of patient-specific therapy and assess the use of each in pharmacotherapy decision-making;
  - 5. summarize the principles of conservative prescribing and identify clinical examples that illustrate each one; and
- 6. given patient-specific scenarios, apply the principles of conservative prescribing in the development of cost-effective therapeutic regimens.

# ACPE #0129-0000-14-041-L04-P

## Legislative Action and Advocacy: What Every Pharmacist MUST Know

Ernest Boyd, PharmD (Hon), CAE, Executive Director, OPA; and Antonio Ciaccia, Director of Government & Public Affairs, OPA

At the completion of this activity, the participant will be able to:

- 1. list the major pieces of state legislation introduced and passed that impact pharmacy;
- 2. discuss the effect of the new federal law regarding compounding on pharmacy practice; and
- 3. define a consult agreement and list the new responsibilities of pharmacists that will be granted upon bill passage.

# ACPE #0129-0000-14-042-L04-P

# Use of Rapid Diagnostic Tests in Community Pharmacy Practice

Michael E. Klepser, PharmD, FCCP, Professor of Pharmacy Practice

Ferris State University

At the completion of this activity, the participant will be able to:

- 1. describe public health opportunities for community pharmacists in the area of rapid diagnostic testing (RDT);
- 2. list the CLIA-waived tests currently available;
- 3. discuss limitations for RDT in the community pharmacy;
- 4. discuss the target disease states where pharmacy can have a public health impact in RDT; and
- 5. describe the business model for RDT in the community pharmacy.

#### ACPE #0129-0000-14-043-L04-P

# Pharmacy Succession: From Planning the Exit to Financing the Purchase

Panel TBA

- 1. identify key points of a successful business transition to a new pharmacy owner;
- 2. describe exit planning strategies for the owner who will sell his/her pharmacy;
- 3. discuss the pros and cons of a having a junior partnership; and
- 4. explain how to secure financing for the purchase of an independent pharmacy.

#### ACPE #0129-0000-14-044-L01-P

#### Pharmacotherapy Update: Lipid Management

Teresa Ash, R.Ph., PharmD, CDE, CLS, BCPS, BCACP, Clinical Supervisor at the Medication Management Clinic, St. Rita's Medical Center. Lima. OH

At the completion of this activity, the participant will be able to:

- 1. explain the pharmacology of newly released lipid therapies;
- 2. apply the NCEP/ATP IV guidelines to clinical practice;
- 3. explain the importance choosing the "right" lipid lowering agent;
- 4. explain the importance combination therapy; and
- 5. evaluate lipid panels and choose appropriate therapy.

#### ACPE #0129-0000-14-045-L01-P

## **New Drug Update 2014**

Karen L. Kier, Ph.D., M.Sc., R.Ph., Director of Assessment and Professor of Clinical Pharmacy Practice Ohio Northern University College of Pharmacy

At the completion of this activity, the participant will be able to:

- 1. describe the pharmacology and therapeutics of the drugs presented that were released to market in the past year;
- 2. list the indications and clinical applications of the drugs presented;
- 3. discuss the most common adverse effects and toxicities, and significant drug-drug interactions reported with these medications; and
  - 4. recognize important patient counseling information on these medications.

#### ACPE #0129-0000-14-046-L01-P

## Bioidentical Hormone Replacement Therapy (BHRT): A Niche Service for Compounders

Cortney Mospan, R.Ph., PharmD, Ohio Pharmacists Association/Uptown Pharmacy

At the completion of this activity, the participant will be able to:

- 1. identify hormones within the body and review their functions;
- 2. summarize signs and symptoms of both hormone deficiency and hormone excess in male and female patients;
- 3. identify appropriate therapies to treat hormone imbalance;
- 4. describe compounding solutions for these patients and niche services for independent pharmacies;
- 5. apply knowledge of hormone imbalances and compounding to clinical scenarios.

### ACPE #0129-0000-14-047-L04-P

# **Culturally-Sensitive Medication Use in Under-Served Populations**

Jeffrey D. Lewis, PharmD, MACM, R.Ph., Associate Dean and Associate Professor of Pharmacy Practice, Cedarville University School of Pharmacy

- 1. describe at least five ways in which cultural differences may challenge the U.S. health care professional in delivering safe and effective and reasonable care in resource-limited environments;
- 2. use a culturally-sensitive dialogue with a patient/caregiver in a resource-limited environment in order to develop an effective care plan (considering the patient, family and community);
- 3. name at least three resources for gaining insight into a given resource-limited culture that will support cost-effective care delivery; and
  - 4. explain the seemingly paradoxical concept, "when helping hurts".

#### ACPE #0129-0000-14-048-L01-P

#### 2014 OTC and Self-Care Challenge

Kristin Casper, R.Ph., PharmD, Associate Professor of Clinical Pharmacy, The Ohio State University College of Pharmacy; and Andrea Wall, R.Ph., Assistant Dean for Student and Alumni Affairs, University of Cincinnati College of Pharmacy

At the completion of this activity, the participant will be able to:

- 1. discuss current topics related to nonprescription medications;
- 2. describe appropriate nonprescription treatment options for common self-care conditions; and
- 3. identify the rationale for the selection of a particular product for a described self-care condition.

## ACPE #0129-0000-14-049-L01-P

# Clostridium difficile: A Review and Update

Mona Thompson, R.Ph., PharmD, Clinical Staff Pharmacist, EMH Elyria Medical Center, Elyria At the completion of this activity, the participant will be able to:

- 1. explain the epidemiology, pathophysiology, transmission for Clostridium difficile infection (CDI);
- 2. recognize the treatment options for managing initial and recurrent CDI;
- 3. identify major risk factors and patients for developing CDI; and
- 4. identify measures to prevent CDI.

## ACPE #0129-0000-14-050-L01-P

#### 2014 Update on Adult Immunizations

Donald Bennett, R.Ph., MBA, Director of Professional Experiential Programs, The Ohio State University College of Pharmacy

At the completion of this activity, the participant will be able to:

- 1. explain recent changes in recommendations for adult immunization from CDC's Advisory Committee on Immunization Practices;
- 2. discuss recent changes in available vaccines and dosage forms;
- 3. identify strategies to overcome barriers of reluctant patients; and
- 4. describe the requirements for maintaining and monitoring vaccine storage conditions.

# ACPE #0129-0000-14-051-L04-P

## **Using Social Media Effectively**

Michael Doherty, R.Ph., PharmD, Director of Experiential Programs, UC; and Antonio Ciaccia, Director of Government and Public Affairs, OPA

- 1. discuss the importance of establishing your social media "brand" as an individual;
- 2. outline practices to maximize the effect of your social media pages;
- 3. recognize the "ripple effect" of social media and how this can be used to amplify your messages to the public;
- 4. explain how to leverage your social media network to promote pharmacy initiatives or your practice setting.